Managing cardiovascular risk in people with chronic kidney disease: A review of the evidence from randomized controlled trials

Therapeutic Advances in Chronic Disease

Volumn 2, Issue 4, 2011, Pages 265-278

  Jun, Min ^a   Jo, Jicheng ^a   Perkovic, Vlado ^a   Jardine, Meg J ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

antioxidant; antiplatelet; blood pressure; bone mineral management; cardiovascular disease; chronic kidney disease; dialysis; end stage kidney disease; fibrate; lipids

Indexed keywords

ACETYLSALICYLIC ACID; ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; ACETYLSALICYLIC ACID PLUS DIPYRIDAMOLE; ALPHA TOCOPHEROL; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIANEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; FIBRINOGEN RECEPTOR ANTAGONIST; FISH OIL; HEPARIN; HIRULOG; LISINOPRIL; PHOSPHATE BINDING AGENT; PICOTAMIDE; PLACEBO; SEVELAMER; SIMVASTATIN; SULFINPYRAZONE; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ANEMIA; BLEEDING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHRONIC KIDNEY DISEASE; HEART FAILURE; HUMAN; ISCHEMIC HEART DISEASE; KIDNEY FUNCTION; LOW DRUG DOSE; MORBIDITY; PATHOPHYSIOLOGY; POST HOC ANALYSIS; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK MANAGEMENT; STROKE; VALIDITY;

EID: 79960041408     PISSN: 20406223     EISSN: 20406231     Source Type: Journal    
DOI: 10.1177/2040622311401775     Document Type: Review

References (129)

1. Abbott K.C. Cruess D.F. Agodoa L.Y. Sawyers E.S. Tveit D.P. Abbott K.C. et al (2004) Early renal insufficiency and late venous thromboembolism after renal transplantation in the United States. Am J Kidney Dis 43: 120–130.
2. Abboud H. Henrich W.L. Abboud H. Henrich W.L. (2010) Clinical practice. Stage IV chronic kidney disease. N Engl J Med 362: 56–65.
3. Abramowitz M. Munter P. Coco M. Southern W. Lotwin I. Hostetter T.H. et al (2010) Serum alkaline phosphatase and phosphate and risk of mortality and hospitalization. Clin J Am Soc Nephrol 5: 1064–1071.
4. ACCORD Study Group Cushman W.C. Evans G.W. Byington R.P. Goff D.C. Jr Grimm R.H. Jr et al (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575–1585.
5. Agarwal R. Alborzi P. Satyan S. Light R.P. Agarwal R. Alborzi P. et al (2009) Dry-weight reduction in hypertensive hemodialysis patients (DRIP): A randomized, controlled trial. Hypertension 53: 500–507.
6. Alborzi P. Patel N. Agarwal R. Alborzi P. Patel N. Agarwal R. (2007) Home blood pressures are of greater prognostic value than hemodialysis unit recordings. Clin J Am Soc Nephrol 2: 1228–1234.
7. Antithrombotic Trialists (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 324: 71–86.
8. Appel L.J. Wright J.T. Jr Greene T. Agodoa L. Astor B.C. Bakris G. et al (2010) Intensive blood-pressure control in hypertensive chronic kidney disease. N Engl J Med 363: 918–929.
9. Armitage J.M. Bowman L. Clarke R.J. Wallendszus K. Bulbulia R. Rahimi K. et al (2010) Effects of homocysteine-lowering with folic acid plus vitamin b 12 vs placebo on mortality and major morbidity in myocardial infarction survivors: A randomized trial. JAMA 303: 2486–2494.
10. Astor B.C. Muntner P. Levin A. Eustace J.A. Coresh J. (2002) Association of kidney function with anemia. The Third National Health and Nutrition Examination Survey (1988–1994). Arch Intern Med 162: 1401–1408.
11. Baigent C. Landry M. Baigent C. Landry M. (2003) Study of heart and renal protection (Sharp). Kidney Int supplement S207–S210.
12. Berger A.K. Duval S. Krumholz H.M. Berger A.K. Duval S. Krumholz H.M. (2003) Aspirin, beta-blocker, and angiotensin-converting enzyme inhibitor therapy in patients with end-stage renal disease and an acute myocardial infarction. J Am Coll Cardiol 42: 201–208.
13. Besarab A. Bolton W.K. Browne J.K. Egrie J.C. Nissenson A.R. Okamoto D.M. et al (1998) The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 339: 584–590.
14. Blacher J. Guerin A.P. Pannier B. Marchaise S.J. London G.M. (2001) Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 38: 938–942.
15. Blacher J. Guerin A.P. Pannier B. Marchais S.J. Safar M.E. London G.M. (1999) Impact of aortic stiffness on survival in end-stage renal disease. Circulation 99: 2434–2439.
16. Block G.A. Hulbert-Shearon T.E. Levin N.W. Port F.K. (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 31: 607–617.
17. Block G.A. Klassen P.S. Lazarus J.M. Ofsthun N. Lowrie E.G. Chertow G.M. (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 8: 2208–2218.
18. Boaz M. Smetana S. Weinstein T. Matas Z. Gafter U. Iaina A. et al (2000) Secondary Prevention with Antioxidants of Cardiovascular Disease in Endstage Renal Disease (SPACE): Randomised placebo-controlled trial. Lancet 356: 1213–1218.
19. Bostom A.G. Carpenter M.A. Kusek J.W. Hunsicker L.G. Pfeffer M.A. Levey A.S. et al (2006) Rationale and Design of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) trial. Am Heart J 152: 448 e441–448 e447.
20. Brenner B.M. Cooper M.E. de Zeeuw D. Keane W.F. Mitch W.E. Parving H.H. et al (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345: 861–869.
21. Brugts J.J. Boersma E. Chonchol M. Deckers J.W. Bertrand M. Remme W.J. et al (2007) The cardioprotective effects of the angiotensin-converting enzyme inhibitor perindopril in patients with stable coronary artery disease are not modified by mild to moderate renal insufficiency: Insights from the EUROPA trial. J Am Coll Cardiol 50: 2148–2155.
22. Chadban S.J. Briganti E.M. Kerr P.G. Dunstan D.W. Welborn T.A. Zimmet P.Z. et al (2003) Prevalence of kidney damage in Australian adults: The Ausdiab Kidney study. J Am Soc Nephrol 14: S131–S138.
23. Chew D.P. Bhatt D.L. Kimball W. Henry T.D. Berger P. Mccullough P.A. et al (2003) Bivalirudin provides increasing benefit with decreasing renal function: A meta-analysis of randomized trials. Am J Cardiol 92: 919–923.
24. Cooper B.A. Branley P. Bulfone L. Collins J.F. Craig J.C. Fraenkel M. et al (2010) A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 363: 609–619.
25. Coresh J. Astor B.C. Greene T. Eknoyan G. Levey A.S. Coresh J. et al (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41: 1–12.
26. Culleton B.F. Walsh M. Klarenbach S.W. Mortis G. Scott-Douglas N. Quinn R.R. et al (2007) Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: A randomized controlled trial. JAMA 298: 1291–1299.
27. Dasgupta A. Steinhubl S.R. Bhatt D.L. Berger P.B. Shao M. Mak K.H. et al (2009) Clinical outcomes of patients with diabetic nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance [CHARISMA] trial). Am J Cardiol 103: 1359–1363.
28. Di Minno G. Cerbone A. Usberti M. Cianciaruso B. Cortese A. Farace M.J. et al (1986) Platelet dysfunction in uremia. II. Correction by arachidonic acid of the impaired exposure of fibrinogen receptors by adenosine diphosphate or collagen. J Lab Clin Med 108: 246–252.
29. Eknoyan G. Beck G.J. Cheung A.K. Daugirdas J.T. Greene T. Kusek J.W. et al (2002) Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 347: 2010–2019.
30. Eleftheriadis T. Antoniadi G. Liakopoulos V. Tsiandoulas A. Barboutis K. Stefanidis I. et al (2006) Propyl gallate-induced platelet aggregation in patients with end-stage renal disease: The influence of the haemodialysis procedure. Nephrology 11: 3–8.
31. Fellstrom B.C. Jardine A.G. Schmieder R.E. Holdaas H. Bannister K. Beutler J. et al (2009) Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med 360: 1395–1407.
32. Foley R.N. Parfrey P.S. Harnett J.D. Kent G.M. Murray D.C. Barre P.E. (1996) The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. Am J Kidney Dis 28: 53–61.
33. Fox C.S. Larson M.G. Leip E.P. Culleton B. Wilson P.W. Levy D. (2004) Predictors of new-onset kidney disease in a community-based population. JAMA 291: 844–850.
34. Francis M.E. Egger P.W. Hostetter T.H. Briggs J.P. (2004) Association between serum homocysteine and markers of impaired kidney function in adults in the United States. Kidney Int 66: 303–312.
35. Frequent Hemodialysis Network (FHN) Trial Group (2010) In-center hemodialysis six times per week versus three times per week. N Engl J Med 363: 2287–2300.
36. Galle J. (2001) Oxidative stress in chronic renal failure. Nephrol Dial Transplant 16: 2135–2137.
37. Galle J. Seibold S. Wanner C. Galle J. Seibold S. Wanner C. (2003) Inflammation in uremic patients: What is the link? Kidney Blood Press Res 26: 65–75.
38. GISEN Group (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano Di Studi Epidemiologici in Nefrologia). Lancet 349: 1857–1863.
39. GISSI-Prevenzione Trial Group (1999) Dietary supplementation with N-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: Results of the GISSI-Prevenzione Trial. Gruppo Italiano Per Lo Studio Della Sopravvivenza Nell'infarto Miocardico. Lancet 354: 447–455.
40. Go A.S. Chertow G.M. Fan D. Mcculloch C.E. Hsu C.Y. Go A.S. et al (2004) Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med 351: 1296–1305.
41. Goodman W.G. Goldin J. Kuizon B.D. Yoon C. Gales B. Sider D. et al (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 342: 1478–1483.
42. Guerin A.P. London G.M. Marchais S.J. Metivier F. (2000) Arterial stiffening and vascular calcifications in end-stage renal disease. Neprhol Dial Transplant 15: 1014–1021.
43. Heart Protection Study Collaborative (2002) MRC / BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 360: 23–33.
44. Heerspink H.J. Ninomiya T. Woodward M. Zoungas S. Cass A. Cooper M. et al (2010) Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 31: 2888–2896.
45. Heerspink H.J. Ninomiya T. Zoungas S. de Zeeuw D. Grobbee D.E. Jardine M.J. et al (2009) Effect of lowering blood pressure on cardiovascular events and mortality in patients on dialysis: A systematic review and meta-analysis of randomised controlled trials. Lancet 373: 1009–1015.
46. Heinz J.M. Kropf S.P. Domrose U.M.D. Westphal S.M.D. Borucki K.M.D. Luley C.M.D. et al (2010) B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: Results of a randomized controlled trial. Circulation 121: 1432–1438.
47. Herzog C.A. Mangrum J.M. Passman R. (2008) Non-coronary heart disease in dialysis patients: Sudden cardiac death and dialysis patients. Semin Dial 21: 300–307.
48. Hou F.F. Zhang X. Zhang G.H. Xie D. Chen P.Y. Zhang W.R. et al (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354: 131–140.
49. House A.A.M.D. Eliasziw M.P. Cattran D.C.M.D. Churchill D.N.M.D. Oliver M.J.M.D. Fine A.M.D. et al (2010) Effect of B-vitamin therapy on progression of diabetic nephropathy: A randomized controlled trial. JAMA 303: 1603–1609.
50. Hung J. Harris P.J. Uren R.F. Tiller D.J. Kelly D.T. (1980) Uremic cardiomyopathy – effect of hemodialysis on left ventricular function in end-stage renal failure. N Engl J Med 302: 547–551.
51. Imai E. Horio M. Iseki K. Yamagata K. Watanabe T. Hara S. et al (2007) Prevalence of chronic kidney disease (CKD) in the Japanese general population predicted by the MDRD equation modified by a Japanese coefficient. Clin Exp Nephrol 11: 156–163.
52. Innes A. Charra B. Burden R.P. Morgan A.G. Laurent G. (1999) The effect of long, slow haemodialysis on patient survival. Nephrol Dial Transplant 14: 919–922.
53. Irish A. Dogra G. Mori T. Beller E. Heritier S. Hawley C. et al (2009) Preventing AVF thrombosis: The rationale and design of the Omega-3 Fatty Acids (Fish Oils) and Aspirin in Vascular Access Outcomes in Renal Disease (FAVOURED) study. BMC Nephrol 10: 1–2.
54. Jafar T.H. Stark P.C. Schmid C.H. Landa M. Maschio G. de Jong P.E. et al (2003) Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Ann Intern Med 139: 244–252.
55. Jamison R.L. Hartigan P. Kaufman J.S. Goldfarb D.S. Warren S.R. Guarino P.D. et al (2007) Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: A randomized controlled trial. JAMA 298: 1163–1170.
56. Januzzi J.L. Jr Snapinn S.M. Dibattiste P.M. Jang I.K. Theroux P. Januzzi J.L. Jr et al (2002) Benefits and Safety of tirofiban among acute coronary syndrome patients with mild to moderate renal insufficiency: Results from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial. Circulation 105: 2361–2366.
57. Jardine M.J. Ninomiya T. Perkovic V. Cass A. Turnbull F. Gallagher M.P. et al (2010) Aspirin is beneficial in hypertensive patients with chronic kidney disease. A post-hoc subgroup analysis of a randomized controlled trial. J Am Coll Cardiol 56: 956–965.
58. Jun M. Foote C. Lv J. Neal B. Patel A. Nicholls S.J. et al (2010) Effects of fibrates on cardiovascular outcomes: A systematic review and meta-analysis. Lancet 375: 1875–1884.
59. Jun M. Heerspink H.J. Ninomiya T. Gallagher M. Bellomo R. Myburgh J. et al (2010) Intensities of renal replacement therapy in acute kidney injury: A systematic review and meta-analysis. Clin J Am Soc Nephrol 5: 956–963.
60. Kalantar-Zadeh K. Abbott K.C. Salahudeen A.K. Kilpatrick R.D. Horwich T.B. Kalantar-Zadeh K. et al (2005) Survival advantages of obesity in dialysis patients. Am J Clin Nutr 81: 543–554.
61. Kalantar-Zadeh K. Block G. Humphreys M.H. Mcallister C.J. Kopple J.D. Kalantar-Zadeh K. et al (2004) A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients. J Am Soc Nephrol 15: 442–453.
62. Kaplan N.M. Kaplan N.M. (2007) Vascular outcome in type 2 diabetes: An advance? Lancet 370: 804–805.
63. Kaufman J.S. O'Connor T.Z. Zhang J.H. Cronin R.E. Fiore L.D. Ganz M.B. et al (2003) Randomized controlled trial of clopidogrel plus aspirin to prevent hemodialysis access graft thrombosis. J Am Soc Nephrol 14: 2313–2321.
64. Kaw D. Malhotra D. Kaw D. Malhotra D. (2006) Platelet dysfunction and end-stage renal disease. Semin Dial 19: 317–322.
65. Keltai M. Tonelli M. Mann J.F. Sitkei E. Lewis B.S. Hawken S. et al (2007) Renal function and outcomes in acute coronary syndrome: Impact of clopidogrel. Eur J Cardiovasc Prev Rehabil 14: 312–318.
66. Kopple J.D. (2005) The phenomenon of altered risk factor patterns or reverse epidemiology in persons with advanced chronic kidney failure. Am J Clin Nutr 81: 1257–1266.
67. Krause M.W. Massing M. Kshirsagar A. Rosamond W. Simpson R.J. Jr Krause M.W. et al (2004) Combination therapy improves survival after acute myocardial infarction in the elderly with chronic kidney disease. Ren Fail 26: 715–725.
68. Lacson E. Jr Wang W. Lester K. Ofsthun N. Lazarus J.M. Hakim R.M. et al (2010) Outcomes associated with in-center nocturnal hemodialysis from a large multicenter program. Clin J Am Soc Nephrol 5: 220–226.
69. Lewis E.J. Hunsicker L.G. Clarke W.R. Berl T. Pohl M.A. Lewis J.B. et al (2001) Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 345: 851–860.
70. Lindler A. Charra B. Sherrard D.J. Scribner B.H. (1974) Accelerated atherosclerosis in prolonged maintenance hemodialysis. N Engl J Med 290: 697–701.
71. Liu Y. Coresh J. Eustace J.A. Longenecker J.C. Jaar B. Fink N.E. et al (2004) Association between cholesterol level and mortality in dialysis patients: Role of inflammation and malnutrition. JAMA 291: 451–459.
72. Locatelli F. Martin-Malo A. Hannedouche T. Loureiro A. Papadimitriou M. Wizemann V. et al (2009) Effect of membrane permeability on survival of hemodialysis patients. J Am Soc Nephrol 20: 645–654.
73. London G.M. Guerin A.P. Marchais S.J. Metivier F. Pannier B. Adda H. (2003) Arterial media calcification: Impact on all-cause mortality and cardiovascular mortality. Nephrol Dial Transplant 18: 1731–1740.
74. Luciak M. Trznadel K. (1991) Free oxygen species metabolism during haemodialysis with different membranes. Nephrol Dial Transplant 6(Suppl 3): 66–70.
75. Mafra D. Guebre-Egziabher F. Fouque D. (2008) Body mass index, muscle and fat in chronic kidney disease: Questions about survival. Nephrol Dial Transplant 23: 2461–2466.
76. Maggi E. Bellazzi R. Falaschi F. Frattoni A. Perani G. Finardi G. et al (1994) Enhanced LDL oxidation in uremic patients: An additional mechanism for accelerated atherosclerosis? Kidney Int 45: 876–883.
77. Mahmoodi B.K. Gansevoort R.T. Veeger N.J. Matthews A.G. Navis G. Hillege H.L. et al (2009) Microalbuminuria and risk of venous thromboembolism. JAMA 301: 1790–1797.
78. Mann J.F. Gerstein H.C. Pogue J. Bosch J. Yusuf S. (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: The HOPE randomized trial. Ann Intern Med 134: 629–636.
79. Mann J.F.E. Sheridan P. McQueen M.J. Held C. Arnold J.M.O. Fodor G. et al (2008) Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease – results of the renal HOPE-2 study. Nephrol Dial Transplant 23: 645–653.
80. Manttari M. Tiula E. Alikoski T. Manninen V. (1995) Effects of hypertension and dyslipidemia on the decline in renal function. Hypertension 26: 670–675.
81. Maschio G. Alberti D. Janin G. Locatelli F. Mann J.F. Motolese M. et al (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group. N Engl J Med 334: 939–945.
82. Mehran R. Nikolsky E. Lansky A.J. Kirtane A.J. Kim Y.H. Feit F. et al (2009) Impact of chronic kidney disease on early (30-day) and late (1-year) outcomes of patients with acute coronary syndromes treated with alternative antithrombotic treatment strategies: An ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) substudy. JACC Cardiovasc Interv 2: 748–757.
83. Moal V. Brunet P. Dou L. Morange S. Sampol J. Berland Y. et al (2003) Impaired expression of glycoproteins on resting and stimulated platelets in uraemic patients. Nephrol Dial Transplant 18: 1834–1841.
84. Muntner P. Coresh J. Smith J.C. Eckfeldt J. Klag M.J. (2000) Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities study. Kidney Int 58: 293–301.
85. National Kidney Foundation (2002) K / DOQI Clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 39: S1–S266.
86. Norris K. Bourgoigne J. Gassman J. Hebert L. Middleton J. Phillips R.A. et al (2006) Cardiovascular outcomes in the African American Study of Kidney Disease and Hypertension (AASK) trial. Am J Kidney Dis 48: 739–751.
87. Palmer S.C. Navaneethan S.D. Craig J.C. Johnson D.W. Tonelli M. Garg A.X. et al (2010) Meta-analysis: Erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med 153: 23–33.
88. Paniagua R. Amato D. Vonesh E. Correa-Rotter R. Ramos A. Moran J. et al (2002) Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 13: 1307–1320.
89. Patrono C. Bachmann F. Baigent C. Bode C. de Caterina R. Charbonnier B. et al (2004) Expert consensus document on the use of antiplatelet agents. The Task Force on the Use of Antiplatelet Agents in Patients with Atherosclerotic Cardiovascular Disease of the European Society of Cardiology. Eur Heart J 25: 166–181.
90. Perkovic V. Ninomiya T. Arima H. Gallagher M. Jardine M. Cass A. et al (2007) Chronic kidney disease, cardiovascular events, and the effects of perindopril-based blood pressure lowering: Data from the PROGRESS study. J Am Soc Nephrol 18: 2766–2772.
91. Peterson J.C. Adler S. Burkart J.M. Greene T. Hebert L.A. Hunsicker L.G. et al (1995) Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med 123: 754–762.
92. Port F.K. Hulbert-Shearon T.E. Wolfe R.A. Bloembergen W.E. Golper T.A. Agodoa L.Y. et al (1999) Predialysis blood pressure and mortality risk in a national sample of maintenance hemodialysis patients. Am J Kidney Dis 33: 507–517.
93. Powell J.R. Oluwaseun O. Woo Y.M. Padmanabhan N. Narasinghan E. Latta C. et al (2009) Ten years experience of in-center thrice weekly long overnight hemodialysis. Clin J Am Soc Nephrol 4: 1097–1101.
94. Rabindranath K.S. Strippoli G.F. Daly C. Roderick P.J. Wallace S. Macleod A.M. (2006) Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. Cochrane Database Syst Rev CD006258–CD006258.
95. Rahman M. Pressel S. Davis B.R. Nwachuku C. Wright J.T. Jr Whelton P.K. et al (2006) Cardiovascular outcomes in high-risk hypertensive patients stratified by baseline glomerular filtration rate. Ann Intern Med 144: 172–180.
96. Reddan D.N. O'Shea J.C. Sarembock I.J. Williams K.A. Pieper K.S. Santoian E. et al (2003) Treatment effects of Eptifibatide in Planned Coronary Stent Implantation in Patients with Chronic Kidney Disease (ESPRIT trial). Am J Cardiol 91: 17–21.
97. Ribeiro C. Ramos A. Brandao A. Reis Rebelo J. Guerra A. Resina C. et al (1998) Cardiac valve calcification in haemodialysis patients: Role of calcium-phosphate metabolism. Nephrol Dial Transplant 13: 2037–2040.
98. Roberts, M., Polkinghorne, K., McDonald, S. and Ierino, F. (2007) Cardiovascular mortality in patients who commence dialysis without clinical evidence of cardiovascular disease. ANZDATA Registry Report 2007.
99. Rocco, M.V. and Kliger A.S. (2010) Prospective randomized trials of more frequent hemodialysis: The Frequent Hemodialysis (FHN) trials of daily in-center and nocturnal home hemodialysis. Late Breaking Clinical Trial Session, 43 rd Annual Meeting and Scientific Exposition of the American Society of Nephrology, Colorado USA, 20 November 2010.
100. Roselaar S.E. Nazhat N.B. Winyard P.G. Jones P. Cunningham J. Blake D.R. (1995) Detection of oxidants in uremic plasma by electron spin resonance spectroscopy. Kidney Int 48: 199–206.
101. Rosendorff C. Black H.R. Cannon C.P. Gersh B.J. Gore J. Izzo J.L. Jr et al (2007) Treatment of hypertension in the prevention and management of ischemic heart disease: A scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and Epidemiology and Prevention. Circulation 115: 2761–2788.
102. Rucker D. Tonelli M. Rucker D. Tonelli M. (2009) Cardiovascular risk and management in chronic kidney disease. Nat Rev Nephrol 5: 287–296.
103. Sarnak M.J. Greene T. Wang X. Beck G. Kusek J.W. Collins A.J. et al (2005) The effect of a lower target blood pressure on the progression of kidney disease: Long-term follow-up of the Modification of Diet in Renal Disease Study. Ann Intern Med 142: 342–351.
104. Sarnak M.J. Levey A.S. (2000) Cardiovascular disease and chronic renal disease: A new paradigm. Am J Kidney Dis 35: S117–S131.
105. Solomon S.D. Rice M.M.K.A.J. Jose P. Domanski M. Sabatine M. et al (2006) Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy in patients with chronic stable coronary disease in the Prevention of Events with Ace Inhibition (PEACE) trial. Circulation 114: 26–31.
106. Steinberg D. Witztum J.L. Steinberg D. Witztum J.L. (2002) Is the oxidative modification hypothesis relevant to human atherosclerosis? Do the antioxidant trials conducted to date refute the hypothesis? Circulation 105: 2107–2111.
107. Steinhubl S.R. Berger P.B. Mann J.T. Fry E.T. de Lago A. Wilmer C. et al (2002) Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: A randomized controlled trial. JAMA 288: 2411–2420.
108. Stenvinkel P. Heimburger O. Paultre F. Diczfalusy U. Wang T. Berglund L. et al (1999) Strong association between malnutrition, inflammation, and atherosclerosis in chronic renal failure. Kidney Int 55: 1899–1911.
109. Stevens L.A. Djurdjev O. Cardew S. Cameron E.C. Levin A. Stevens L.A. et al (2004) Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: Evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 15: 770–779.
110. Strippoli G.F. Navaneethan S.D. Johnson D.W. Perkovic V. Pellegrini F. Nicolucci A. et al (2008) Effects of statins in patients with chronic kidney disease: Meta-analysis and meta-regression of randomised controlled trials. Br Med J 336: 645–651.
111. Suki W.N. Zabaneh R. Cangiano J.L. Reed J. Fischer D. Garrett L. et al (2007) Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 72: 1130–1137.
112. Suliman M.E. Qureshi A.R. Barany P. Stenvinkel P. Filho J.C. Anderstam B. et al (2000) Hyperhomocysteinemia, nutritional status, and cardiovascular disease in hemodialysis patients. Kidney Int 57: 1727–1735.
113. Tepel M. van der Giet M. Statz M. Jankowski J. Zidek W. Tepel M. et al (2003) The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: A randomized, controlled trial. Circulation 107: 992–995.
114. Tozawa M. Iseki K. Iseki C. Oshiro S. Ikemiya Y. Takishita S. (2002) Influence of smoking and obesity on the development of proteinuria. Kidney Int 62: 956–962.
115. Tveit D.P. Hypolite I.O. Hshieh P. Cruess D. Agodoa L.Y. Welch P.G. et al (2002) Chronic dialysis patients have high risk for pulmonary embolism. Am J Kidney Dis 39: 1011–1017.
116. US Preventive Services Task Force (2009) Aspirin for the prevention of cardiovascular disease: US preventive services task force recommendation statement. Ann Intern Med 150: 396–404.
117. van der Weerd N.C. Penne E.L. van Den Dorpel M.A. Grooteman M.P. Nube M.J. Bots M.L. et al (2008) Haemodiafiltration: Promise for the future? Nephrol Dial Transplant 23: 438–443.
118. van Eps C.L. Jeffries J.K. Johnson D.W. Campbell S.B. Isbel N.M. Mudge D.W. et al (2010) Quality of life and alternate nightly nocturnal home hemodialysis. Hemodial Int 14: 29–38.
119. Vaziri N.D. (2006) Dyslipidaemia of chronic renal failure: The nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 290: F262–F272.
120. Vianna A.C.A. Mocelin A.J. Matsuo T. Morais-Filho D. Largura A. Delfino V.A. et al (2007) Uremic hyperhomocysteinemia: A randomized trial of folate treatment for the prevention of cardiovascular events. Hemodial Int 11: 210–216.
121. VITATOPS Trial Study Group (2010) B Vitamins in Patients with Recent Transient Ischaemic Attack or Stroke in the Vitamins to Prevent Stroke (VITATOPS) trial: A randomised, double-blind, parallel, placebo-controlled trial. Lancet Neurol 9: 855–865.
122. Walsh M. Culleton B. Tonelli M. Manns B. Walsh M. Culleton B. et al (2005) A systematic review of the effect of nocturnal hemodialysis on blood pressure, left ventricular hypertrophy, anemia, mineral metabolism, and health-related quality of life. Kidney Int 67: 1500–1508.
123. Wanner C. Krane V. Marz W. Olschewski M. Mann J.F. Ruf G. et al (2005) Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med 353: 238–248.
124. Wattanakit K. Cushman M. Stehman-Breen C. Heckbert S.R. Folsom A.R. Wattanakit K. et al (2008) Chronic kidney disease increases risk for venous thromboembolism. J Am Soc Nephrol 19: 135–140.
125. Yach D. Leeder S.R. Bell J. Kistnasamy B. Yach D. Leeder S.R. et al (2005) Global chronic diseases. Science 307: 317–318.
126. Yap S. (2003) Classical homocystinuria: Vascular risk and its prevention. J Inherit Metab Dis 26: 259–265.
127. Young E.W. Albert J.M. Satayathum S. Goodkin D.A. Pisoni R.L. Akiba T. et al (2005) Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice and Patterns Study. Kidney Int 67: 1179–1187.
128. Yusuf S. Dagenais G. Pogue J. Bosch J. Sleight P. (2000) Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342: 154–160.
129. Zoungas S. McGrath B.P. Branley P. Kerr P.G. Muske C. Wolfe R. et al (2006) Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid supplementation Trial (ASFAST) in chronic renal failure: A multicenter, randomized, controlled trial. J Am Coll Cardiol 47: 1108–1116.